Skip to main content

The Role of Community Pharmacy and Pharmacotherapy in Obesity Management

  • Chapter
  • First Online:
Bariatric Surgery in Clinical Practice

Part of the book series: In Clinical Practice ((ICP))

  • 334 Accesses

Abstract

Obesity, a physiological state affecting around 30% of the UK population (Foresight 2004), is an independent risk factor for many long-term conditions with significant financial consequences for Health Services and national economies. The estimated costs of obesity in the UK, for example are believed to be at least £500 million a year in treatment costs to the NHS, and possibly, in excess of £200 million to the wider economy. These healthcare costs are predicted to escalate over the coming years as the number of obese people in the population increases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1105–16.

    CAS  PubMed  Google Scholar 

  • Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107–17. https://doi.org/10.1056/NEJMoa1808721.

    Article  CAS  PubMed  Google Scholar 

  • Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP. Maintained intentional weight loss reduces cardiovascular outcomes: results from the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523–30. https://doi.org/10.1111/j.1463-1326.2011.01554.x.

    Article  CAS  PubMed  Google Scholar 

  • Cochrane Systematic Review. Rimonabant for overweight or obesity. 2006; https://doi.org/10.1002/14651858.CD006162.pub2.

  • Department of Health. Choosing Health through pharmacy—a programme for pharmaceutical public health 2005–2015. (Department-of-Health, London, 2005).

    Google Scholar 

  • Department-of-Health. Choosing health: making health choices easier. London: Department of Health; 2004. p. 207.

    Google Scholar 

  • Department-of-Health. Our Health, our care, our say. A new direction for community services. http://www.dh.gov.uk/assetRoot/04/12/74/59/04127459.pdf. (2006).

  • Foresight. Tackling obesities: future choice—project report. London: Government Department of Science; 2004.

    Google Scholar 

  • Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert Opinion on Drug Safety. 2017;16:27–39. https://doi.org/10.1080/14740338.2017.1247807.

    Article  CAS  PubMed  Google Scholar 

  • Meera S, Tressler L, Maguire T, Van Den Berg M. A pharmacy led obesity management programme. Pharm J. 2008;

    Google Scholar 

  • National Institute for Health and Clinical Excellence. Drugs for the treatment of overweight and obese adults. NICE technology Appraisal Guidance 144 (2008).

    Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE). Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. (2006).

    Google Scholar 

  • Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646–67. https://doi.org/10.1111/bcp.14210. Epub 2020 Feb 4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pi-Sunyer X. The look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep. 2014;3:387–91. https://doi.org/10.1007/s13668-014-0099-x

    Article  CAS  Google Scholar 

  • Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs. 2010;10(5):321–34. https://doi.org/10.2165/11584800-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  • Wanless D. Securing out future health: taking a long-term view. London: HM Treasury; 2002.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Terrance A. Maguire .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maguire, T.A. (2022). The Role of Community Pharmacy and Pharmacotherapy in Obesity Management. In: Haslam, D., Malhotra, A., Capehorn, M.S. (eds) Bariatric Surgery in Clinical Practice. In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-83399-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-83399-2_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-83398-5

  • Online ISBN: 978-3-030-83399-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics